ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 632,71
0,00%
Dow Jones
40 211,72
0,53%
DAX
18 600,18
0,00%
Brent Oil
83,705
-0,75%
Bitcoin
63 416,61
-2,21%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Intellia Therapeutics Inc (NTLA)

  7. Intellia Therapeutics Inc (NTLA) Actualités

NTLA

Intellia Therapeutics (NTLA)

Intellia Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:NTLA
DateHeureSourceTitreSymboleSociété
03/06/202003h00GlobeNewswire Inc.Intellia Therapeutics Announces Pricing of Public Offering of Common StockNASDAQ:NTLAIntellia Therapeutics Inc
01/06/202022h53Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)NASDAQ:NTLAIntellia Therapeutics Inc
01/06/202022h00GlobeNewswire Inc.Intellia Therapeutics Announces Proposed Public Offering of Common StockNASDAQ:NTLAIntellia Therapeutics Inc
01/06/202013h14Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:NTLAIntellia Therapeutics Inc
01/06/202013h00PR Newswire (US)Regeneron and Intellia Therapeutics Expand Collaboration to Develop CRISPR/Cas9-Based TreatmentsNASDAQ:NTLAIntellia Therapeutics Inc
28/05/202023h24Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:NTLAIntellia Therapeutics Inc
12/05/202012h00GlobeNewswire Inc.Intellia Therapeutics Reports Progress on CRISPR/Cas9 AML Cancer Therapy Using Proprietary Cell Engineering Process at the 23...NASDAQ:NTLAIntellia Therapeutics Inc
07/05/202022h42Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:NTLAIntellia Therapeutics Inc
07/05/202013h30GlobeNewswire Inc.Intellia Therapeutics Announces First Quarter 2020 Financial ResultsNASDAQ:NTLAIntellia Therapeutics Inc
05/05/202022h48Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:NTLAIntellia Therapeutics Inc
30/04/202013h50GlobeNewswire Inc.Intellia Therapeutics Names David Lebwohl, M.D., Chief Medical OfficerNASDAQ:NTLAIntellia Therapeutics Inc
30/04/202013h30GlobeNewswire Inc.Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2020 Earnings and Company UpdatesNASDAQ:NTLAIntellia Therapeutics Inc
28/04/202022h30GlobeNewswire Inc.Intellia Therapeutics to Present New Preclinical Data from Its CRISPR/Cas9 Programs at the 23rd Annual Meeting of the Ame...NASDAQ:NTLAIntellia Therapeutics Inc
24/04/202022h11Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:NTLAIntellia Therapeutics Inc
24/04/202022h04Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:NTLAIntellia Therapeutics Inc
31/03/202013h30GlobeNewswire Inc.FDA Accepts Investigational New Drug Application for CRISPR/Cas9-Based Sickle Cell Disease Therapeutic Candidate Developed Un...NASDAQ:NTLAIntellia Therapeutics Inc
30/03/202020h55Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:NTLAIntellia Therapeutics Inc
27/02/202023h33Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:NTLAIntellia Therapeutics Inc
27/02/202022h49Edgar (US Regulatory)Annual Report (10-k)NASDAQ:NTLAIntellia Therapeutics Inc
27/02/202013h30GlobeNewswire Inc.Intellia Therapeutics Announces Fourth Quarter and Full-Year 2019 Financial ResultsNASDAQ:NTLAIntellia Therapeutics Inc
20/02/202013h30GlobeNewswire Inc.Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2019 Earnings and Company UpdateNASDAQ:NTLAIntellia Therapeutics Inc
14/02/202017h44Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:NTLAIntellia Therapeutics Inc
10/02/202013h30GlobeNewswire Inc.Intellia Therapeutics Presents New Data From Its Engineered Cell Therapy and In Vivo Programs at Keystone Symposia’s Engine...NASDAQ:NTLAIntellia Therapeutics Inc
09/01/202013h30GlobeNewswire Inc.Intellia Therapeutics Highlights Recent Progress and Anticipated 2020 MilestonesNASDAQ:NTLAIntellia Therapeutics Inc
26/11/201914h00GlobeNewswire Inc.Intellia Therapeutics to Present at Evercore ISI 2nd Annual HealthCONx ConferenceNASDAQ:NTLAIntellia Therapeutics Inc
31/10/201912h30GlobeNewswire Inc.Intellia Therapeutics Announces Third Quarter 2019 Financial ResultsNASDAQ:NTLAIntellia Therapeutics Inc
24/10/201914h00GlobeNewswire Inc.Intellia Therapeutics to Hold Conference Call to Discuss Third Quarter 2019 Earnings and Company UpdateNASDAQ:NTLAIntellia Therapeutics Inc
24/10/201913h30GlobeNewswire Inc.Intellia Therapeutics Presents In Vivo and Ex Vivo Data at the 2019 Annual Congress of the European Society of Gene and Cell ...NASDAQ:NTLAIntellia Therapeutics Inc
16/10/201914h00GlobeNewswire Inc.Intellia Therapeutics Announces Presentations at the 2019 Annual Congress of the European Society of Gene and Cell Therapy (E...NASDAQ:NTLAIntellia Therapeutics Inc
30/09/201914h00GlobeNewswire Inc.Intellia Therapeutics to Present at October Healthcare Investor ConferencesNASDAQ:NTLAIntellia Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:NTLA

Dernières Valeurs Consultées

NASDAQ
GOOGL
Alphabet
USI
USTECH100
US Tech 100
COIN
ETHUSD
Ethereum
EU
CAP
Capgemini
EU
SGO
Cie de SaintGobain
EU
GLE
Societe Generale
EU
CS
Axa
EU
BN
Danone
EU
BEL20
Bel 20
NYSE
MRK
Merck
NASDAQ
MSFT
Microsoft
EU
ACA
Credit Agricole
EU
VIV
Vivendi
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés